Microbiotica Announces Positive Results From Its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) CAMBRIDGE, United Kingdom, May 18, 2026 (GLOBE NEWSWIRE) --  Microbiotica, a clinical-stage...

Microbiome Therapy Could Help Drug-Resistant Melanoma Patients

Microbiotica, a microbiome-focused biotech based in Cambridge in the U.K., has achieved good Phase Ib results in a trial of its microbiome therapy for patients with advanced melanoma skin cancer. The therapy, currently known as MB097, is designed to be given to patients who have not previously responded to immunotherapy in addition to a checkpoint inhibitor pembrolizumab. MB097 was developed to reverse the drug resistance seen in these patients …

Microbiotica reports positive results for MB097 in advanced melanoma

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment